Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02182440 · ClinicalTrials.gov registry record · Phase 2
A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI
A Phase 2 study of Acute Kidney Injury, sponsored by AM-Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
- 20
- Study locations
NCT02182440 is a Phase 2 study of Acute Kidney Injury that has completed, run by AM-Pharma. The registered enrollment target is 301 participants, below the 2,327-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02182440, a Phase 2 study of Acute Kidney Injury, has completed, sponsored by AM-Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether recombinant Alkaline Phosphatase (recAP) is effective and save, and to determine the most effective dose, in the treatment of patients with acute kidney injury caused by sepsis.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL recAP
Study Locations (20)
Other
- University Hospital Antwerpen - Antwerp
- Cliniques Universitaires Saint Luc-UCL - Brussels
- CHU Brugmann - Brussels
- UZ Brussel - Brussels
- Oblastni nemocnice Kolin, a.s. - Kolín
- Fakultni nemocnice Plzen - Pilsen
- Helsingin Yliopistollinen Keskussairaala - Helsinki
- Kuopion Yliopistollinen Sairaala - Kuopio
Tyrol
- Medizinische Universität Innsbruck - Innsbruck
- Universitätsklinik für Allgemeine und Chirurgische Intensivmedizin - Innsbruck
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- Tampa General Hospital, Division Emergency Medicine - Tampa
Idaho
- Eastern Idaho Medical Consultants LLC - Idaho Falls
Ohio
- University of Cincinnati Medical Center - Cincinnati
Pennsylvania
- UPMC - Pittsburgh
Texas
- University of Texas Houston Medical School - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2014-12-18 |
| Est. Completion | 2017-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02182440
The ClinicalTrials.gov registry entry for NCT02182440 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,327-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (87% lower). The listed sponsor is AM-Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02182440 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Tyrol, Alabama.
Frequently Asked Questions
What is clinical trial NCT02182440 about?
NCT02182440 is a clinical study titled "A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI". The purpose of this study is to determine whether recombinant Alkaline Phosphatase (recAP) is effective and save, and to determine the most effective dose, in the treatment of patients with acute kidney injury caused by sepsis.
What is the current status of trial NCT02182440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2014-12-18. Estimated completion is 2017-09-27.
What conditions does trial NCT02182440 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT02182440?
The interventions under investigation include: Placebo (OTHER), recAP (BIOLOGICAL).
Who is sponsoring clinical trial NCT02182440?
This trial is sponsored by AM-Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02182440 being conducted?
This trial has 20 study locations across Alabama, Florida, Idaho, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
RECRUITING · Phase 2
-
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
RECRUITING · Phase 2
-
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial)
RECRUITING · Phase 2
-
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.